Norikatsu Miyoshi1,2, Shiki Fujino3,4, Masayuki Ohue5, Masayoshi Yasui5, Yusuke Takahashi5, Keijiro Sugimura5, Akira Tomokuni5, Hirofumi Akita5, Shogo Kobayashi3, Hidenori Takahashi5, Takeshi Omori5, Hiroshi Miyata5, Masahiko Yano5. 1. Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, 2-2-E2 Yamadaoka, Suita, Osaka, 565-0871, Japan. nmiyoshi@gesurg.med.osaka-u.ac.jp. 2. Division of Next-generation Innovative Cancer Research and Translational Medicine, Osaka International Cancer Institute, 3-1-69, Ohtemae, Chuo-ku, Osaka, 541-8567, Japan. nmiyoshi@gesurg.med.osaka-u.ac.jp. 3. Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, 2-2-E2 Yamadaoka, Suita, Osaka, 565-0871, Japan. 4. Division of Next-generation Innovative Cancer Research and Translational Medicine, Osaka International Cancer Institute, 3-1-69, Ohtemae, Chuo-ku, Osaka, 541-8567, Japan. 5. Department of Surgery, Osaka International Cancer Institute, 3-1-69, Ohtemae, Chuo-ku, Osaka, 541-8567, Japan.
Abstract
PURPOSE: The POU5F1 gene, which encodes the POU domain, class 5, transcription factor 1 (also known as Oct-4), is expressed in embryonic stem cells where it regulates pluripotency and proliferation. Few studies have examined the expression and significance of POU5F1 in cancer tissues. The aim of this study was to clarify its significance in colorectal cancer (CRC). METHODS: The study included 95 patients who underwent surgery for CRC from 2009 to 2011. The correlations between the POU5F1 gene expression and the clinical parameters were assessed in these patients. The serum TP53 expression levels were also examined by an enzyme-linked immunosorbent assay. RESULTS: Patients with a high POU5F1 expression were significantly more likely to have a poor prognosis than those with a low expression. In contrast, patients with a low POU5F1 expression had a better disease-free survival after curative surgical resection than those with a high expression (P = 0.007). Multivariate analyses showed that the POU5F1 expression (P = 0.003) and lymph node metastasis (P < 0.001) were significantly correlated with the disease-free survival. The prognosis was significantly related to the serum TP53 levels, according to the POU5F1 expression. CONCLUSION: The POU5F1 expression was suggested to be a prognostic factor in patients with CRC.
PURPOSE: The POU5F1 gene, which encodes the POU domain, class 5, transcription factor 1 (also known as Oct-4), is expressed in embryonic stem cells where it regulates pluripotency and proliferation. Few studies have examined the expression and significance of POU5F1 in cancer tissues. The aim of this study was to clarify its significance in colorectal cancer (CRC). METHODS: The study included 95 patients who underwent surgery for CRC from 2009 to 2011. The correlations between the POU5F1 gene expression and the clinical parameters were assessed in these patients. The serum TP53 expression levels were also examined by an enzyme-linked immunosorbent assay. RESULTS:Patients with a high POU5F1 expression were significantly more likely to have a poor prognosis than those with a low expression. In contrast, patients with a low POU5F1 expression had a better disease-free survival after curative surgical resection than those with a high expression (P = 0.007). Multivariate analyses showed that the POU5F1 expression (P = 0.003) and lymph node metastasis (P < 0.001) were significantly correlated with the disease-free survival. The prognosis was significantly related to the serum TP53 levels, according to the POU5F1 expression. CONCLUSION: The POU5F1 expression was suggested to be a prognostic factor in patients with CRC.
Authors: Yuin-Han Loh; Qiang Wu; Joon-Lin Chew; Vinsensius B Vega; Weiwei Zhang; Xi Chen; Guillaume Bourque; Joshy George; Bernard Leong; Jun Liu; Kee-Yew Wong; Ken W Sung; Charlie W H Lee; Xiao-Dong Zhao; Kuo-Ping Chiu; Leonard Lipovich; Vladimir A Kuznetsov; Paul Robson; Lawrence W Stanton; Chia-Lin Wei; Yijun Ruan; Bing Lim; Huck-Hui Ng Journal: Nat Genet Date: 2006-03-05 Impact factor: 38.330
Authors: Anguraj Sadanandam; Costas A Lyssiotis; Krisztian Homicsko; Eric A Collisson; William J Gibb; Stephan Wullschleger; Liliane C Gonzalez Ostos; William A Lannon; Carsten Grotzinger; Maguy Del Rio; Benoit Lhermitte; Adam B Olshen; Bertram Wiedenmann; Lewis C Cantley; Joe W Gray; Douglas Hanahan Journal: Nat Med Date: 2013-04-14 Impact factor: 53.440
Authors: M Kornmann; A Formentini; C Ette; D Henne-Bruns; M Kron; S Sander; W Baumann; E-D Kreuser; L Staib; K H Link Journal: Eur J Surg Oncol Date: 2008-03-03 Impact factor: 4.424
Authors: Oliver F Bathe; Scot Dowden; Francis Sutherland; Elijah Dixon; Charles Butts; David Bigam; Barb Walley; Dean Ruether; Scott Ernst Journal: BMC Cancer Date: 2004-07-10 Impact factor: 4.430
Authors: Ka Chen; Hongliang Liu; Zhensheng Liu; Sheng Luo; Edward F Patz; Patricia G Moorman; Li Su; Sipeng Shen; David C Christiani; Qingyi Wei Journal: Int J Cancer Date: 2019-02-01 Impact factor: 7.396
Authors: Simone G van Breda; Karen Mathijs; Harm-Jan Pieters; Virág Sági-Kiss; Gunter G Kuhnle; Panagiotis Georgiadis; Giovanna Saccani; Giovanni Parolari; Roberta Virgili; Rashmi Sinha; Gert Hemke; Yung Hung; Wim Verbeke; Ad A Masclee; Carla B Vleugels-Simon; Adriaan A van Bodegraven; Theo M de Kok Journal: Mol Nutr Food Res Date: 2021-08-27 Impact factor: 6.575
Authors: Lydia Lam; Tien Tien; Mark Wildung; Laura White; Rance K Sellon; Janean L Fidel; Eric A Shelden Journal: PLoS One Date: 2022-09-13 Impact factor: 3.752